Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer
Cost analysis of S1 and XELOX as adjuvant therapy for gastric cancer
复制标题
S1和XELOX辅助治疗胃癌的成本分析
DOI：
10.1097/cad.0b013e328361bef2
复制
发表时间：
2013-08-01
影响因子：
2.3
通讯作者：
Li, Qiu
中科院分区：
文献类型：
--
作者：
He, Jianping;Wen, Feng;Li, Qiu
根据美国国家综合癌症网络（NCCN）的指南，S1和XALIX（卡培他滨+奥沙利铂）均被推荐为胃癌的辅助治疗。本研究比较了两种方案的货币成本，假设两种方案的疗效相同。从病历中收集了188例患者的化疗费用数据，其中S1组91例，XALX组97例。成本分为直接成本（化疗、住院、静脉通路和检查）、不良事件相关治疗成本和社会（旅行和时间）成本。每例患者每周期的S1和XCRIX的总直接成本分别为1938 ±236美元和2317 ±315美元。S1的总不良事件相关成本和社会成本分别比XALX低27美元和9美元。每例患者每周期的S1和XCRIX的总成本分别为1994 ±322美元和2410 ±391美元。S1的总费用比Xcadix平均患者的总费用低17.3%。所有差异均具有统计学意义。在中国，当考虑到所有医疗资源时，S1可能是一种更实惠的胃癌辅助治疗选择。
Both S1 and XELOX (capecitabine+oxaliplatin) have been recommended as an adjuvant treatment for gastric cancer according to the guidelines of the National Comprehensive Cancer Network (NCCN). This study compared the two regimens in terms of monetary costs, assuming equal efficacy of both regimens. Chemotherapy cost data of 188 patients were collected from the medical records, 91 for the S1 group and 97 for XELOX. Costs were classified as direct costs (chemotherapy, hospitalization, venous access, and tests), adverse event-related treatments costs, and societal (travel and time) costs. The total direct costs of S1 and XELOX per cycle per patient were $1938±236 and $2317±315, respectively. S1 cost $27 and $9 less than XELOX on total adverse event-related costs and societal costs, respectively. The total costs of S1 and XELOX were $1994±322 versus $2410±391 per cycle per patient, respectively. The total cost of S1 was 17.3% less than that of XELOX for the average patient. All the differences were statistically significant. S1, compared with XELOX, could be a more affordable option as an adjuvant treatment for gastric cancer when all healthcare resources are taken into account in China.